ctDNA monitoring using tumor-informed copy number analysis

Authors:

Abstract
Methods to detect circulating tumor DNA (ctDNA) enable minimally invasive responsive monitoring of cancer dynamics. However, sensitive and cost-effective methods are still lacking. Current methods for detecting cancer signals in shallow whole-genome sequencing (sWGS) data from cell-free DNA (cfDNA) via copy number aberration (CNA) analysis typically have a limit of detection of approximately 3% tumor fraction (TF). We developed informCNA, a bioinformatics method that leverages CNA information from sWGS of tumor or pre-treatment plasma samples with high TF as references, enabling ctDNA detection down to 0.2% TF across multiple cancer types. In 177 serial plasma samples from 18 patients with ovarian cancer, informCNA showed high concordance with the standard serum protein marker CA-125 and identified recurrence a median of 3.7 months earlier than CA-125 test. These results demonstrate the potential of personalized CNA analysis through sWGS for estimating ctDNA burden, enabling precise and cost-effective disease monitoring and early detection of relapse.
Funding Information
  • Cancer Research UK (C507/A27657,C9545/A29580,SEBINT-2024/100003,C1287/A26886,EDDRPG-May24/100002 & C36857/A27548)
  • NIHR Cambridge Biomedical Research Centre (BRC-1215-20014)
  • NIHR Cambridge Biomedical Research Centre (NIHR203312)
  • Mark Foundation For Cancer Research (RG95043)
  • Cancer Research UK Cambridge Institute, University of Cambridge (C9685/A25177)
  • Cancer Research UK Cambridge Institute, University of Cambridge (CTRQQR- 2021\100012)
  • Addenbrooke's Charitable Trust, Cambridge University Hospitals (ACT 9800)
  • CRUK City of London Major Centre Awards (C7893/A26233 and CTRQQR-2021\100004)
  • CRUK-Royal College of Surgeons of England Clinician Scientist Fellowship (C64667/A27958)
  • Breast Cancer Now Toby Robins Research Centre (CTR-Q5-Y3)